Odyssey Health (OTC: ODYY) continues to dedicate its operational strategy toward the acquisition and creation of lifesaving medical products. “Odyssey’s portfolio includes medical device candidates and pharmaceutical products in development that are responsive to conditions such as heart disease, foreign object-induced choking, neurodegenerative disorders, and brain concussion injuries. One drug product designed to treat mild traumatic injury within the first few minutes after an incident is advancing in a phase 1 clinical human trial following on preclinical lab animal tests that provided encouraging data, CEO Michael Redmond said in a June interview,” a recent article reads. “No U.S. Food and Drug Administration (‘FDA’)-approved drug exists at this point, creating a particular opportunity for the company. The other drug substance is a novel compound intended to treat neurodegenerative Niemann-Pick disease, which leaves patients with an average lifespan of five to 20 years beyond diagnosis.”
To view the full article, visit https://ibn.fm/zqPL0
About Odyssey Health Inc. (formerly Odyssey Group International Inc.)
Odyssey Health is a medical company focused on developing life enhancing medical solutions. Odyssey’s corporate mission is to develop and commercialize exceptional technologies that provide meaningful medical solutions. The company is focused on technologies that provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork